


IThis listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



in which

Het denotes a mono- or bicyclic aromatic heterocyclic radical having from 1 to 3 N, O and/or S atoms which is mono- or disubstituted by Hal,

R¹ denotes A, which may be mono-, di- or trisubstituted by S(O)_mA, Ph, NH₂, NHA, NA₂, OH, OA, PO(OA)₂, ethynyl, vinyl or O(CH₂)_nPh,

R² denotes H, Hal or A,

R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,

A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,

Ph denotes phenyl,
Hal denotes F, Cl, Br or I,
n denotes 1, 2, 3, 4, 5 or 6,
m denotes 0, 1 or 2,
and pharmaceutically usable ~~derivatives, solvates, salts and~~ stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently Amended) Compounds according to Claim 1, in which
R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted by ethynyl, phenyl, OA, OH or OA,
~~and~~ pharmaceutically usable ~~derivatives, solvates, salts and~~ stereoisomers thereof, including mixtures thereof in all ratios.
3. (Currently Amended) Compounds according to Claim 1, in which
R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,
~~and~~ pharmaceutically usable ~~derivatives, solvates, salts and~~ stereoisomers thereof, including mixtures thereof in all ratios.
4. (Currently Amended) Compounds according to claim 1, in which
R² denotes H, methyl or F,
~~and~~ pharmaceutically usable ~~derivatives, solvates, salts and~~ stereoisomers thereof, including mixtures thereof in all ratios.
5. (Previously Presented) Compounds according to claim 1, in which
Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl

or oxazolyl, each of which is mono- or disubstituted by Hal,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof,
including mixtures thereof in all ratios.

6. (Currently Amended) ~~Compounds~~ Compounds according to claim 1, in which
- Het denotes thienyl, furyl, pyrrolyl, benzofuranyl, benzo[b]thienyl, thiazolyl
or oxazolyl, each of which is mono- or disubstituted by Hal,
- R¹ denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be substituted
by ethynyl, phenyl, OA, OH or OA,
- R² denotes H, Hal or A,
- R³ denotes 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-
yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl,
2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-
iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-
yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,
- A denotes H, unbranched, branched or cyclic alkyl having 1-10 C atoms,
- Ph denotes phenyl,
- Hal denotes F, Cl, Br or I,
- n denotes 1, 2, 3, 4, 5 or 6,
- m denotes 0, 1 or 2,
- ~~and/or~~ pharmaceutically usable derivatives, solvates, salts ~~and/or~~ stereoisomers
thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to Claim 1 of the formula ~~selected~~
~~from the group consisting of~~

1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-
propylsemicarbazide,


1-(5-chlorothien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-

(prop-2-ynyl)semicarbazide,
 1-(3-chlorothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,
 1-(5-bromothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,
 1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,
 1-(5-chlorothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-benzylsemicarbazide,
 1-(5-bromothiien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,
 1-(3-chlorobenzo[b]thienyl-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,
 1-(3-chlorothiien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,
 1-(5-chlorothiien-2-ylcarbonyl)-4-[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,
 1-(3-chlorothiien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,
 1-(3-chlorothiien-2-ylcarbonyl)-4-[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]-2-cyclopropylmethylsemicarbazide,
 1-(3-chlorothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,
 1-(5-chlorothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-(2-methoxyethyl)semicarbazide,
 1-(5-chlorothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,
 1-(5-bromothiien-2-ylcarbonyl)-4-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-2-cyclopropylmethylsemicarbazide,

~~and/or pharmaceutically usable derivatives, solvates, salts and/or stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently Amended) Process for the preparation of compounds of the formula I according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates, comprising salts and/or stereoisomers thereof, characterised in that comprising reacting~~

a) a compound of the formula II



in which

R¹, R² and R³ have the meaning indicated in Claim 1,

~~is reacted with a compound of the formula III~~



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group,
and

Het has the meaning indicated in Claim 1,

~~and/or converting~~

a base or acid of the formula I ~~is converted~~ into one of its salts.

9. (Currently Amended) ~~Compounds~~ A method of inhibiting coagulation factor Xa, comprising administering to a host in need thereof, a compound of the formula I according to claim 1 as inhibitors of coagulation factor Xa.
10. (Currently Amended) ~~Compounds~~ A method of inhibiting coagulation factor VIIa, comprising administering to a host in need thereof, a compound of the formula I according to claim 1 as inhibitors of coagulation factor VIIa.
11. (Currently Amended) ~~Medicaments~~ a pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and/or stereoisomers thereof, including mixtures thereof in all ratios, and, if desired, pharmaceutically acceptable excipients and/or adjuvants.
12. (Currently Amended) ~~Medicaments comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and~~ A pharmaceutical composition according to claim 11, further comprising at least one further medicament active ingredient.
13. (Currently Amended) ~~Use of compounds according to claim 1 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament~~ A method for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.

14. (Currently Amended) Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I according to claim 1 and/or pharmaceutically usable ~~derivatives, solvates, salts and~~ or stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
15. (Currently Amended) ~~Use of compounds of the formula I according to claim 1 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,~~
~~for the preparation of a medicament~~ A method for the treatment of thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios, in combination with at least one further medicament active ingredient.
16. (New) A method for the treatment of thromboembolic diseases, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.
17. (New) A method for the treatment of thrombosis, comprising administering to a host in need thereof, an effective amount of a compound of claim 1, or pharmaceutically usable salts or stereoisomers thereof, including mixtures thereof in all ratios.